➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Johnson and Johnson
Moodys
McKinsey
Merck

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

PARAPLATIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Paraplatin, and what generic alternatives are available?

Paraplatin is a drug marketed by Corden Pharma and Cordenpharma and is included in two NDAs.

The generic ingredient in PARAPLATIN is carboplatin. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the carboplatin profile page.

US ANDA Litigation and Generic Entry Outlook for Paraplatin

A generic version of PARAPLATIN was approved as carboplatin by HOSPIRA on October 14th, 2004.

  Start Trial

Summary for PARAPLATIN
Drug patent expirations by year for PARAPLATIN
Recent Clinical Trials for PARAPLATIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
MedSIRPhase 2
Hoffmann-La RochePhase 2
OncoQuest Pharmaceuticals Inc.Phase 3

See all PARAPLATIN clinical trials

Paragraph IV (Patent) Challenges for PARAPLATIN
Tradename Dosage Ingredient NDA Submissiondate
PARAPLATIN INJECTABLE;INJECTION carboplatin 019880
PARAPLATIN INJECTABLE;INTRAVENOUS carboplatin 020452

US Patents and Regulatory Information for PARAPLATIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Corden Pharma PARAPLATIN carboplatin INJECTABLE;INJECTION 019880-001 Mar 3, 1989 DISCN Yes No   Start Trial   Start Trial   Start Trial
Cordenpharma PARAPLATIN carboplatin INJECTABLE;INTRAVENOUS 020452-004 Jan 15, 2004 DISCN Yes No   Start Trial   Start Trial   Start Trial
Cordenpharma PARAPLATIN carboplatin INJECTABLE;INTRAVENOUS 020452-001 Jul 14, 2003 DISCN Yes No   Start Trial   Start Trial   Start Trial
Corden Pharma PARAPLATIN carboplatin INJECTABLE;INJECTION 019880-002 Mar 3, 1989 DISCN Yes No   Start Trial   Start Trial   Start Trial
Corden Pharma PARAPLATIN carboplatin INJECTABLE;INJECTION 019880-003 Mar 3, 1989 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PARAPLATIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Corden Pharma PARAPLATIN carboplatin INJECTABLE;INJECTION 019880-001 Mar 3, 1989   Start Trial   Start Trial
Cordenpharma PARAPLATIN carboplatin INJECTABLE;INTRAVENOUS 020452-004 Jan 15, 2004   Start Trial   Start Trial
Cordenpharma PARAPLATIN carboplatin INJECTABLE;INTRAVENOUS 020452-001 Jul 14, 2003   Start Trial   Start Trial
Corden Pharma PARAPLATIN carboplatin INJECTABLE;INJECTION 019880-003 Mar 3, 1989   Start Trial   Start Trial
Cordenpharma PARAPLATIN carboplatin INJECTABLE;INTRAVENOUS 020452-002 Jul 14, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.